MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

Phase 4
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Metformin
Drug: Voglibose
Drug: Acarbose
First Posted Date
2014-01-30
Last Posted Date
2019-03-13
Lead Sponsor
Takeda
Target Recruit Count
494
Registration Number
NCT02049814

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

Phase 2
Completed
Conditions
Healthy Volunteers
Norovirus, Prevention
Interventions
Biological: Hepatitis A Vaccine
Biological: Norovirus Bivalent VLP Vaccine
First Posted Date
2014-01-17
Last Posted Date
2017-08-08
Lead Sponsor
Takeda
Target Recruit Count
420
Registration Number
NCT02038907
Locations
🇧🇪

Universiteit Antwerpen, Edegem, Belgium

🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis

Phase 3
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Vedolizumab placebo
Drug: Vedolizumab
First Posted Date
2014-01-17
Last Posted Date
2019-04-25
Lead Sponsor
Takeda
Target Recruit Count
292
Registration Number
NCT02039505

Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Drug: Vedolizumab placebo
Drug: Vedolizumab
First Posted Date
2014-01-17
Last Posted Date
2019-12-09
Lead Sponsor
Takeda
Target Recruit Count
157
Registration Number
NCT02038920

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Phase 3
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Vonoprazan
Drug: Esomeprazole
Drug: Rabeprazole sodium
First Posted Date
2014-01-16
Last Posted Date
2016-10-17
Lead Sponsor
Takeda
Target Recruit Count
20
Registration Number
NCT02037477

Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome

Completed
Conditions
Overactive Bladder Syndrome
Interventions
Drug: Propiverine
First Posted Date
2013-12-31
Last Posted Date
2013-12-31
Lead Sponsor
Takeda
Target Recruit Count
437
Registration Number
NCT02024945

Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus

Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Pioglitazone/metformin hydrochloride
First Posted Date
2013-12-31
Last Posted Date
2016-11-22
Lead Sponsor
Takeda
Target Recruit Count
1103
Registration Number
NCT02024971

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

Phase 3
Withdrawn
Conditions
Type 2 Diabetes Mellitus
Chronic Kidney Disease
Interventions
Drug: Placebo
Drug: Fasiglifam
Drug: Antihyperglycemic therapy
First Posted Date
2013-12-19
Last Posted Date
2014-01-27
Lead Sponsor
Takeda
Registration Number
NCT02015780

Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)

Completed
Conditions
Hypertension
Interventions
Drug: Candesartan cilexetil / hydrochlorothiazide
First Posted Date
2013-12-19
Last Posted Date
2018-11-09
Lead Sponsor
Takeda
Target Recruit Count
3222
Registration Number
NCT02016183

Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"

Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Pioglitazone
First Posted Date
2013-12-06
Last Posted Date
2019-01-24
Lead Sponsor
Takeda
Target Recruit Count
18223
Registration Number
NCT02002975
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy